Baxdrostat demonstrates efficacy in resistant hypertension

Mechanism of Action

Baxdrostat targets aldosterone, a hormone regulating salt and water retention, a key factor in uncontrolled hypertension. By inhibiting aldosterone production, the drug addresses a fundamental mechanism of the disease, offering a targeted solution for patients who have exhausted standard therapies. The study’s lead investigator, Professor Bryan Williams of UCL’s Institute of Cardiovascular Science, highlighted that “the drug’s effectiveness persisted for up to 32 weeks without safety concerns, a critical factor in long-term management of chronic conditions.”

Trial Results and Efficacy

The BaxHTN trial, which included nearly 800 patients across 214 clinics, demonstrated a notable decrease in blood pressure, with patients experiencing an average reduction of 9–10 mmHg. This advancement is critical in addressing a global health issue, as hypertension affects over 1.3 billion individuals worldwide, with more than half a billion cases concentrated in Asia. The international BaxHTN trial was presented at the European Society of Cardiology (ESC) Congress 2025 and published in the New England Journal of Medicine (NEJM), reflecting its scientific validity and clinical significance.

“the drug’s effectiveness persisted for up to 32 weeks without safety concerns, a critical factor in long-term management of chronic conditions.”

Baxdrostat operates by inhibiting aldosterone synthase, an enzyme central to aldosterone production. This mechanism differs from traditional antihypertensive drugs, which often target the renin-angiotensin-aldosterone system (RAAS) through alternative pathways. Aldosterone promotes sodium reabsorption in the kidneys, leading to increased fluid retention and elevated blood pressure. By blocking aldosterone synthase, Baxdrostat disrupts this process, reducing salt and water retention and lowering blood pressure. This approach represents a first-in-class innovation in treating resistant hypertension, as noted by AstraZeneca’s press release, which stated that the drug is the first aldosterone synthase inhibitor (ASI) to demonstrate statistically significant reductions in systolic blood pressure (SBP) in Phase III trials. “the drug is the first aldosterone synthase inhibitor (ASI) to demonstrate statistically significant reductions in systolic blood pressure (SBP) in Phase III trials.”

Efficacy in 24-Hour and Nighttime Blood Pressure

The drug’s efficacy was further validated through its impact on 24-hour and nighttime blood pressure. A prespecified analysis showed that the 2mg dose reduced 24-hour SBP by 16.9 mmHg, indicating sustained control beyond daytime measurements. This is particularly important, as nighttime hypertension is associated with higher cardiovascular risks. The trial also revealed that baxdrostat tripled the odds of achieving the new blood pressure target of <130/80 mmHg, as recommended by the ESC 2024 guidelines. These findings suggest that the drug not only addresses immediate blood pressure spikes but also contributes to long-term cardiovascular risk reduction.

Global Applicability and Safety Profile

The BaxHTN trial’s results were robust, with the 2mg dose of baxdrostat achieving a placebo-adjusted reduction in SBP of 9.8 mmHg at week 12. This corresponds to a 15.7 mmHg reduction from baseline, a figure exceeding the 9–10 mmHg reported in the ScienceDaily article. The 1mg dose also showed similar reductions, indicating a dose-dependent effect without excessive side effects. Notably, the drug was well-tolerated, with hyperkalaemia (elevated potassium levels) occurring in only 1.1% of patients, compared to 0.0% in the placebo group. This low incidence of hyperkalaemia is significant, as it mitigates a common concern with aldosterone-modulating drugs, which can disrupt electrolyte balance.

Broader Public Health Impact

The trial’s global reach, involving over 20,000 patients, highlights its broad applicability. Patients from diverse regions, including the UK, the U.S., and Asia, participated, ensuring the findings are generalizable. The study’s success in multiple subgroups, including those with comorbidities like diabetes or kidney disease, further strengthens its clinical relevance. Professor Williams noted that the 10 mmHg placebo-adjusted reduction in SBP is linked to lower cardiovascular risks, a finding that aligns with the NEJM’s emphasis on the drug’s potential to improve long-term outcomes for patients with resistant hypertension.

Addressing a Major Public Health Challenge

The potential impact of baxdrostat extends beyond individual patients, addressing a major public health challenge. Hypertension is a leading risk factor for heart attacks, strokes, and kidney disease, contributing to over 7 million deaths annually. The drug’s ability to lower blood pressure by up to 16.9 mmHg in 24-hour measurements could significantly reduce these risks, particularly in low-income regions where access to advanced treatments is limited. The study estimates that baxdrostat could help up to half a billion people globally, including 10 million in the UK, where the new blood pressure target of <130/80 mmHg is now standard.

Addressing Hypertension in Asia

“the drug is the first aldosterone synthase inhibitor (ASI) to demonstrate statistically significant reductions in systolic blood pressure (SBP) in Phase III trials.”

In Asia, where over half of the world’s hypertension cases are concentrated, the drug’s availability could alleviate the burden on healthcare systems. The trial’s inclusion of patients from diverse geographic regions underscores its potential to address hypertension in both developed and resource-limited settings. AstraZeneca’s acquisition of baxdrostat from CinCor Pharma in 2023 highlights the drug’s commercial viability, with plans for regulatory filings in major markets. This global approach aligns with the World Health Organization’s (WHO) goals to reduce hypertension-related mortality through improved access to effective treatments.

Regulatory Path and Future Research

While the BaxHTN trial’s results are promising, the path to widespread adoption involves regulatory approvals and further research. AstraZeneca’s press release noted that the drug is currently in the final stages of regulatory review, with plans to file for approval in key markets. The drug’s first-in-class status as an aldosterone synthase inhibitor (ASI) positions it as a potential standard of care for resistant hypertension, though its long-term effects beyond 32 weeks require additional study. Ongoing trials are also exploring its use in primary aldosteronism, a condition characterized by excessive aldosterone production, and in patients with chronic kidney disease, where hypertension is a common complication.

Broader Implications for Hypertension Treatment

The success of baxdrostat also raises questions about the broader landscape of hypertension treatment. The ESC 2024 guidelines’ lower blood pressure targets have increased the demand for more effective therapies, and baxdrostat’s ability to meet these targets could reshape clinical practice. However, challenges remain, including ensuring equitable access to the drug in low-income countries and addressing potential side effects, such as hyperkalaemia, through patient monitoring. As the global hypertension epidemic continues to grow, innovations like baxdrostat represent a critical step toward more personalized and effective treatment strategies.